KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Profit After Tax (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Profit After Tax for 13 consecutive years, with -$105.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 60.25% to -$105.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$345.9 million, a 47.62% decrease, with the full-year FY2025 number at -$345.9 million, down 47.62% from a year prior.
  • Profit After Tax was -$105.3 million for Q4 2025 at Xenon Pharmaceuticals, down from -$90.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$15.4 million in Q3 2021 to a low of -$105.3 million in Q4 2025.
  • A 5-year average of -$48.3 million and a median of -$46.1 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 12533.71% in 2021, then decreased 14.87% in 2024.
  • Xenon Pharmaceuticals' Profit After Tax stood at -$25.6 million in 2021, then tumbled by 46.28% to -$37.4 million in 2022, then decreased by 19.65% to -$44.7 million in 2023, then plummeted by 46.81% to -$65.7 million in 2024, then crashed by 60.25% to -$105.3 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Profit After Tax are -$105.3 million (Q4 2025), -$90.9 million (Q3 2025), and -$84.7 million (Q2 2025).